Adagene(US:ADAG) Jin Rong Jie·2025-08-13 14:13Core Viewpoint - Tianyan Pharmaceuticals (ADAG) has experienced a significant stock price increase of 10.47%, reaching $2.11 per share, with a total market capitalization of $99.447 million. However, the company reported a substantial decline in revenue and net profit for the fiscal year ending December 31, 2024, indicating financial challenges ahead [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, a decrease of 99.43% year-over-year [1]. - The company recorded a net loss attributable to shareholders of $33.4241 million, reflecting a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on developing novel cancer immunotherapies based on original antibodies [1]. - The company utilizes a powerful platform that combines computational biology and artificial intelligence to create new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, with the goal of creating globally innovative or best-in-class products [1].